{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:54Z","timestamp":1740144174945,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["13\/128\/01"],"award-info":[{"award-number":["13\/128\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40273-016-0436-6","type":"journal-article","created":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T06:56:40Z","timestamp":1470034600000},"page":"1241-1253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Vedolizumab for Treating Moderately to Severely Active Crohn\u2019s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6914-1990","authenticated-orcid":false,"given":"Rachid","family":"Rafia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Scope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Harnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,1]]},"reference":[{"key":"436_CR1","unstructured":"National Institute for Health and Care Excellence [NICE]. Guide to the methods of technology appraisal 2013. 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/1-foreword . Accessed June 2016."},{"key":"436_CR2","unstructured":"Rafia R, Scope A, Harnan S, Stevens JW, Stevenson M, Sutton A, et al. ERG report: vedolizumab for the treatment of adults with moderately to severely active Crohn\u2019s disease: a single technology appraisal. School of Health and Related Research (ScHARR). 2014. http:\/\/www.nets.nihr.ac.uk\/__data\/assets\/pdf_file\/0018\/133650\/ERGReport-13-128-01.pdf . Accessed June 2016."},{"key":"436_CR3","unstructured":"Rafia R, Scope A, Stevenson M. Vedolizumab for the treatment of adults with moderately to severely active Crohn\u2019s disease: critique of the evidence submitted by the company following the ACD. School of Health and Related Research (ScHARR). 2015. https:\/\/www.nice.org.uk\/guidance\/TA352\/documents\/crohns-disease-moderate-to-severe-vedolizumab-committee-papers2 . Accessed June 2016."},{"key":"436_CR4","unstructured":"NICE. Final appraisal determination: vedolizumab for treating moderately to severely active Crohn\u2019s disease after prior therapy. 2015. https:\/\/www.nice.org.uk\/guidance\/TA352\/documents\/crohns-disease-moderate-to-severe-vedolizumab-final-appraisal-determination-document2 . Accessed June 2016."},{"key":"436_CR5","unstructured":"Takeda Pharmaceuticals. Vedolizumab for the for the treatment of adult patients with moderately to severely active Crohn\u2019s disease: manufacturer\u2019s submission to the National Institute for Health and Care Excellence. 2014. https:\/\/www.nice.org.uk\/guidance\/TA352\/documents\/crohns-disease-moderate-to-severe-vedolizumab-committee-papers-part-12 . Accessed June 2016."},{"issue":"9853","key":"436_CR6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ. Crohn\u2019s disease. Lancet. 2012;380(9853):571\u2013607.","journal-title":"Lancet"},{"issue":"5","key":"436_CR7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.2010.224154","volume":"60","author":"C Mowat","year":"2011","unstructured":"Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571\u2013607.","journal-title":"Gut"},{"issue":"1","key":"436_CR8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1155\/1999\/506915","volume":"13","author":"EM Yoshida","year":"1999","unstructured":"Yoshida EM. The Crohn\u2019s disease activity index, its derivatives and the inflammatory bowel disease questionnaire: a review of instruments to assess Crohn\u2019s disease. Can J Gastroenterol. 1999;13(1):65\u201373.","journal-title":"Can J Gastroenterol"},{"key":"436_CR9","unstructured":"National Institute for Health and Care Excellence [NICE]. TA187: infliximab (review) and adalimumab for the treatment of Crohn\u2019s disease. 2010. https:\/\/www.nice.org.uk\/guidance\/ta187 . Accessed June 2016."},{"key":"436_CR10","unstructured":"Takeda Pharma A\/S. Entyvio EMA summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002782\/WC500168528.pdf . Accessed June 2016."},{"key":"436_CR11","unstructured":"National Institute for Health and Care Excellence [NICE]. Vedolizumab for treating moderately to severely active Crohn\u2019s disease after prior therapy: final scope. 2014. https:\/\/www.nice.org.uk\/guidance\/TA352\/documents\/crohns-disease-moderate-to-severe-vedolizumab-final-scope2 . Accessed June 2016."},{"issue":"8","key":"436_CR12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan B, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321.","journal-title":"N Engl J Med."},{"issue":"3","key":"436_CR13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","volume":"147","author":"BE Sands","year":"2014","unstructured":"Sands BE, Feagan B, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, et al. Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618\u201327.","journal-title":"Gastroenterology"},{"issue":"2","key":"436_CR14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn W, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323\u201333.","journal-title":"Gastroenterology"},{"issue":"15","key":"436_CR15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer S, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029\u201335.","journal-title":"N Engl J Med"},{"issue":"12","key":"436_CR16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","volume":"146","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829\u201338.","journal-title":"Ann Intern Med."},{"issue":"2","key":"436_CR17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","volume":"6","author":"M Watanabe","year":"2012","unstructured":"Watanabe M, Hibi T, Lomax KG, Paulson SK, Chao J, Alam MS, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn\u2019s disease. J Crohns Colitis. 2012;6(2):160\u201373.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"436_CR18","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","volume":"142","author":"P Rutgeerts","year":"2012","unstructured":"Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial. Gastroenterology. 2012;142(5):1102\u201311.","journal-title":"Gastroenterology"},{"issue":"9317","key":"436_CR19","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan B, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT\u00a0I randomised trial. Lancet. 2002;359(9317):1541\u20139.","journal-title":"Lancet"},{"issue":"9","key":"436_CR20","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","volume":"56","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Hanauer S, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, et al. Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC\u00a0II trial. Gut. 2007;56(9):1232\u20139.","journal-title":"Gut"},{"issue":"1","key":"436_CR21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn W, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132(1):52\u201365.","journal-title":"Gastroenterology"},{"issue":"3","key":"436_CR22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.7861\/clinmedicine.12-3-235","volume":"12","author":"L Blackmore","year":"2012","unstructured":"Blackmore L, Harris A. A prospective study of infliximab withdrawal after 12\u00a0months of treatment in patients with Crohn\u2019s disease: how will NICE guidance affect patient care? Clinical Medicine. 2012;12(3):235\u20138.","journal-title":"Clinical Medicine"},{"issue":"3","key":"436_CR23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2036.2009.04033.x","volume":"30","author":"K Bodger","year":"2009","unstructured":"Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn\u2019s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30(3):265\u201374.","journal-title":"Aliment Pharmacol Ther"},{"key":"436_CR24","unstructured":"National Institute for Health and Care Excellence [NICE]. Vedolizumab for treating moderately to severely active Crohn\u2019s disease after prior therapy: appraisal consultation document. 2015. https:\/\/www.nice.org.uk\/guidance\/TA352\/documents\/crohns-disease-moderate-to-severe-vedolizumab-appraisal-consultation-document2 . Accessed June 2016."},{"key":"436_CR25","unstructured":"Takeda Pharmaceuticals. Company ACD response: Crohn\u2019s disease (moderate to severe). 2015. https:\/\/www.nice.org.uk\/guidance\/TA352\/documents\/crohns-disease-moderate-to-severe-vedolizumab-committee-papers2 . Accessed June 2016."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-016-0436-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-016-0436-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-016-0436-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T15:38:06Z","timestamp":1498318686000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-016-0436-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["436"],"URL":"https:\/\/doi.org\/10.1007\/s40273-016-0436-6","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2016,8,1]]}}}